Literature DB >> 4623743

Treatment of chronic drug-resistant pulmonary tuberculosis with rifampin and ethambutol.

C W Jeanes, A G Jessamine, L Eidus.   

Abstract

Twenty patients with chronic pulmonary tuberculosis completed eight months of rifampin-ethambutol treatment. Half the patients received daily 600 mg. rifampin and 25 mg./kg. ethambutol for the first two months and subsequently 15 mg./kg. The others received the same dosage of ethambutol and 450 mg. rifampin daily. The average time of sputum conversion was seven weeks and 11 weeks in the two groups respectively. The patients tolerated these drug regimens well.Rifampin blood levels and urinary excretion were studied monthly during the therapy. They indicated that after a short period of treatment the elimination of this drug became faster owing to increased excretion of rifampin, and particularly of its desacetyl metabolite, in the bile. Liver damage resulted in a slower excretion rate. Rifampin should be taken on an empty stomach because simultaneous food intake reduces the peak blood concentration.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4623743      PMCID: PMC1940582     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  2 in total

1.  Rifampicin and ethambutol in the treatment of drug resistant and far advanced pulmonary tuberculosis (with a note on capreomycin).

Authors:  A Pines; H Raafat; G M Siddiqui
Journal:  J Ir Med Assoc       Date:  1970-03

2.  Rifampicin in the retreatment and original treatment of advanced pulmonary tuberculosis.

Authors:  A Gyselen
Journal:  Bull Int Union Tuberc       Date:  1970-06
  2 in total
  8 in total

1.  The use and protection of rifampin as an anti-tuberculosis agent.

Authors:  O Clarke
Journal:  Can Fam Physician       Date:  1973-02       Impact factor: 3.275

2.  Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  A H Diacon; R F Patientia; A Venter; P D van Helden; P J Smith; H McIlleron; J S Maritz; P R Donald
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

3.  Pediatric antimicrobial therapy. II.

Authors:  M I Marks; R M Shapera; M Brazeau
Journal:  Can Med Assoc J       Date:  1973-07-21       Impact factor: 8.262

4.  Treatment of pulmonary tuberculosis in a patient on maintenance haemodialysis.

Authors:  F W Smith; G R Catto; M MacLeod
Journal:  Postgrad Med J       Date:  1974-07       Impact factor: 2.401

5.  Editorial: Rifampin in the treatment of tuberculosis.

Authors:  S Grzybowshi
Journal:  Can Med Assoc J       Date:  1974-05-04       Impact factor: 8.262

6.  Therapeutic efficacy of rifampin in newly detected pulmonary tuberculosis.

Authors:  A G Jessamine; G L Gale; L Eidus
Journal:  Can Med Assoc J       Date:  1974-05-04       Impact factor: 8.262

Review 7.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.